GENMAB A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,934 DKK | -0.04% |
|
-5.91% | -10.28% |
| May. 21 | Genmab A/S Reaffirms Financial Guidance for 2024 | CI |
| May. 21 | Genmab A/S completed the acquisition of ProfoundBio, Inc. | CI |
| Sales 2024 * | 19.8B 2.88B | Sales 2025 * | 23.62B 3.43B | Capitalization | 125B 18.13B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.67B 679M | Net income 2025 * | 6.61B 961M | EV / Sales 2024 * | 4.99 x |
| Net cash position 2024 * | 25.9B 3.77B | Net cash position 2025 * | 32.35B 4.7B | EV / Sales 2025 * | 3.91 x |
| P/E ratio 2024 * |
28.5
x | P/E ratio 2025 * |
20.4
x | Employees | 2,286 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab A/S
More recommendations
More press releases
More news
| 1 day | -1.05% | ||
| 1 week | -3.37% | ||
| Current month | -1.12% | ||
| 1 month | -1.02% | ||
| 3 months | +2.03% | ||
| 6 months | -6.14% | ||
| Current year | -10.23% |
1 week
1 906.00
2 067.00
1 month
1 906.002 088.00
Current year
1 825.002 227.00
1 year
1 825.002 828.00
3 years
1 825.003 327.00
5 years
1 082.503 327.00
10 years
204.803 327.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
| Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 15-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.64% | 200 M€ | +16.95% | ||
| 1.28% | 48 M€ | +9.38% | ||
| 1.01% | 85 M€ | +1.47% | ||
| 0.75% | 17 M€ | +7.15% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-29 | 1,932 | -0.13% | 38 825 |
| 24-05-28 | 1,934 | -1.05% | 118,736 |
| 24-05-27 | 1,955 | +1.48% | 124,780 |
| 24-05-24 | 1,926 | -4.86% | 429,468 |
| 24-05-23 | 2,025 | -1.46% | 106,682 |
Delayed Quote Nasdaq Copenhagen, May 28, 2024 at 10:59 am EDT
More quotes
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,934
DKK
Average target price
2,466
DKK
Spread / Average Target
+27.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.23% | 18.18B | |
| +9.83% | 115B | |
| +10.80% | 105B | |
| -10.84% | 22.71B | |
| -1.69% | 21.83B | |
| -41.92% | 16.52B | |
| -15.11% | 16.01B | |
| +6.62% | 14.14B | |
| +17.53% | 10.71B | |
| -30.73% | 7.6B |
- Stock Market
- Equities
- GMAB Stock
